TABLE 1.
Patient characteristics and treatments
| Patient characteristics | n | % |
|---|---|---|
| Patients | 45 | 100 |
| Gender | ||
| Male | 27 | 60 |
| Female | 18 | 40 |
| Median age, years (range) | 70 (27–86) | |
| <65 years | 19 | 42 |
| ≥65 years | 26 | 58 |
| Melanoma stage | ||
| Unresectable melanoma stage IIIC | 3 | 7 |
| Unresectable melanoma stage IV | 42 | 93 |
| Treatments during the study | ||
| Ipilimumab | 27 | 60 |
| Ipilimumab/Nivolumab | 7 | 16 |
| Pembrolizumab | 9 | 20 |
| Nivolumab | 2 | 4 |
| Response to treatments during the study | ||
| Therapy success | 13 | 29 |
| Complete response | 1 | 2 |
| Partial response | 9 | 20 |
| Stable disease | 3 | 7 |
| Therapy failure | 29 | 64 |
| Unknown outcome | 3 | 7 |
| Treatments prior to the study | ||
| Systemic treatment | ||
| Chemotherapy | 1 | 2 |
| BRAF and MEK inhibitors | 9 | 20 |
| Checkpoint inhibitors | 3 | 7 |
| Number of systemic treatments | ||
| 0 | 32 | 71 |
| 1 | 9 | 20 |
| 2 | 4 | 9 |
| Radiotherapy | ||
| Cerebral radiation | 3 | 7 |
| Peripheral radiation | 5 | 11 |
| Adjuvant immunotherapy | ||
| Adjuvant interferon immunotherapy | 2 | 4 |
| Mutanome Engineered RNA Immunotherapy (MERIT) | 3 | 7 |
| Transarterial chemoembolization (TACE) | 1 | 2 |
| Electro cancer therapy (ECT) | 1 | 2 |
The percentages refer to the total number of patients (n = 45) and are rounded. Prior to the study, patients received up to two previous systemic treatments. Three patients had already been treated with different immune checkpoint inhibitors: One patient received Nivolumab, the other Ipilimumab, and the third one received Ipilimumab followed later by Pembrolizumab.
Abbreviations: BRAF, B‐Raf proto‐oncogene kinase; MEK, mitogen‐activated protein kinase kinase.